UAE to become Middle East’s vaccine center with China’s contribution
It's reported that experts from Sinopharm and the UAE health department regularly communicate and share information with each other, collecting and analyzing problems, providing feedback during the experiment and inoculation process on a regular basis so that Sinopharm's vaccine will be further compliant, improved and recognized by more countries.
According to insiders, a recent rise in the number of buyers from Middle Eastern and African countries purchasing COVID-19 vaccines through the UAE has slowed the pace of vaccination there to avoid supply shortages. The UAE also recently decided to establish a vaccine production facility in Abu Dhabi in cooperation with Sinopharm to meet the growing global demand for vaccines.
'First country in the Middle East producing COVID-19 vaccines'
"We are in the advanced stages of discussion with our key strategic partners and are happy to announce that local manufacturing of the vaccine will be done in the UAE," said Ashish Koshy, chief executive of Abu Dhabi-based G42 Healthcare, UAE newspaper The National reported on January 5.
"We intend to commence production this year," The National quoted Koshy as saying. The UAE is going to produce the COVID-19 vaccine under license from the Chinese drug maker, which will not only meet local but also anticipated global demand, it reported.
The UAE will start producing Chinese vaccines later this year under the license of Chinese pharmaceutical manufacturers, meaning that it will become the first country in the Middle East to produce COVID-19 vaccines, said German business news magazine WirtschaftsWoche. Its production plan will go beyond meeting the target of achieving herd immunity in the UAE.
With UAE manufacturing Sinopharm Vaccine this year, that would mean there will be more vaccine available for countries who need it. This means higher chance of getting the allocation for Malaysia.
1. New bamboo processing plant and R&D centre in Jingzhou, China goes into full production in the fourth quarter of 2020 2. ready-to-harvest raw bamboo surrounding the plant will serve as a steady source of raw material supply in the production of bamboo products 3. global bamboo market at US$68.8 billion (RM286 billion) in 2018 4.Autocity rental RM11 million
It was reported that Chinese vaccines could not find enough old people to conduct 3 stage trials both in China or overseas.Therefore it is limited up to age of 59 only. Old people are advised not to take until further tests are conducted.
Stop promote vaksin lah. all the vaksin promoters get lost pls. now left last defence at 10sen for bamboo dreamer lah. Enuf of your vaksin dream lah. Correct?
SIS amount only 30,000,000 not so much, but too often n price too low, should be 10% discount, crazy. It seems that my earlier calculation of share price was right.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
UlarSawa
35,552 posts
Posted by UlarSawa > 2021-01-28 20:39 | Report Abuse
left only one vaksin promoter still so hard working. better rest lah. Correct?